Background: supratotal resection is advocated in lower-grade-gliomas (LGGs) based on theoretical advantages, but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecular-defined LGGs with oncological outcomes. Methods: 460 presumptive LGGs included; 404 resected; 347 were LGGs, 319 IDH-mutated, 28 wildtype. All patients had clinical, imaging, molecular data. Resection aimed at supratotal resection without any patient or tumor a-priori selection. The association of Extent-of-Resection (EOR), categorized on volumetric-FLAIR-images as residual-tumor-volume, along with post-surgical-management with Progression-free-survival (PFS), malignant-progression-free-survival (MPFS), and Overall-Survival (OS) assessed by univariate, multivariate, propensity-score-analysis. The study mainly focused on IDH-mutated-LGGs, the "typical LGGs". Results: Median follow-up:6.8 years(IQR:5-8). Out of 319 IDH-mutated-LGGs, 190 (59.6%) progressed, median PFS:4.7 years(95%CI:4-5.3). Total and supratotal resection obtained in 39% and 35% of patients of IDH1-mutated tumors. In IDH-mutated, most patients in partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months(95%CI:25-36) in subtotal, 46 months(95%CI:38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular-subtypes and grade. At random-forest-analysis, PFS strongly associated with EOR,RT, previous treatment. In the propensity-score analysis, EOR associated with PFS (HR,0.03;95%CI,0.01-0.13). MPFS occurred in 32.1% of subtotal-total groups; 1 event in supratotal. EOR, grade-III, previous treatment correlated to MPFS. At random-forest analysis, OS associated with EOR as well. Conclusions: Supratotal resection strongly associated with PFS, MPFS and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.

Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas / M. Rossi, L. Gay, F. Ambrogi, M.C. Nibali, T. Sciortino, G. Puglisi, A. Leonetti, C. Mocellini, M. Caroli, S. Cordera, M. Simonelli, F. Pessina, P. Navarria, A. Pace, R. Soffietti, R. Rudà, M. Riva, L. Bello. - In: NEURO-ONCOLOGY. - ISSN 1522-8517. - 23:5(2021), pp. 812-826. [10.1093/neuonc/noaa225]

Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas

M. Rossi
Primo
;
L. Gay
Secondo
;
F. Ambrogi;M.C. Nibali;T. Sciortino;G. Puglisi;A. Leonetti;M. Simonelli;M. Riva
Penultimo
;
L. Bello
2021

Abstract

Background: supratotal resection is advocated in lower-grade-gliomas (LGGs) based on theoretical advantages, but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecular-defined LGGs with oncological outcomes. Methods: 460 presumptive LGGs included; 404 resected; 347 were LGGs, 319 IDH-mutated, 28 wildtype. All patients had clinical, imaging, molecular data. Resection aimed at supratotal resection without any patient or tumor a-priori selection. The association of Extent-of-Resection (EOR), categorized on volumetric-FLAIR-images as residual-tumor-volume, along with post-surgical-management with Progression-free-survival (PFS), malignant-progression-free-survival (MPFS), and Overall-Survival (OS) assessed by univariate, multivariate, propensity-score-analysis. The study mainly focused on IDH-mutated-LGGs, the "typical LGGs". Results: Median follow-up:6.8 years(IQR:5-8). Out of 319 IDH-mutated-LGGs, 190 (59.6%) progressed, median PFS:4.7 years(95%CI:4-5.3). Total and supratotal resection obtained in 39% and 35% of patients of IDH1-mutated tumors. In IDH-mutated, most patients in partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months(95%CI:25-36) in subtotal, 46 months(95%CI:38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular-subtypes and grade. At random-forest-analysis, PFS strongly associated with EOR,RT, previous treatment. In the propensity-score analysis, EOR associated with PFS (HR,0.03;95%CI,0.01-0.13). MPFS occurred in 32.1% of subtotal-total groups; 1 event in supratotal. EOR, grade-III, previous treatment correlated to MPFS. At random-forest analysis, OS associated with EOR as well. Conclusions: Supratotal resection strongly associated with PFS, MPFS and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
Malignant-progression-free-survival; Overall-Survival; Progression-free-survival; lower-grade gliomas; supratotal resection
Settore MED/27 - Neurochirurgia
Settore MED/06 - Oncologia Medica
13-ott-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
noaa225.pdf

embargo fino al 13/10/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.37 MB
Formato Adobe PDF
1.37 MB Adobe PDF Visualizza/Apri
noaa225.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.42 MB
Formato Adobe PDF
2.42 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/775827
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 28
social impact